0.02
-0.018(-46.75%)
Currency In USD
Address
Room 325, 55 Claverick Street
Providence, RI 02903
United States of America
Phone
401-444-7375
Sector
Healthcare
Industry
Biotechnology
Employees
7
First IPO Date
November 08, 2021
| Name | Title | Pay | Year Born |
| Dr. M. Michelle Berrey M.D., M.P.H. | Chief Executive Officer | 0 | 1967 |
| Dr. Jonathan Kurtis M.D., Ph.D. | Founder, Chairman of Scientific Advisory Board & Director | 0 | 1969 |
| Ms. Jolie G. Kahn CPA, Esq. | Chief Financial Officer | 0 | 1965 |
| Dr. Chirinjeev Baboo Kathuria M.B.A., M.D. | Founder & Executive Chairman of the Board | 0 | 1966 |
| Dr. Jack A. Elias M.D. | Founder, Chairman of Scientific Advisory Board | 0 | 1952 |
| Dr. Inderjote Kathuria M.B.A., M.D. | Chief Strategy Officer | 0 | 1968 |
| Mr. Robert John Sweeney | Chief Accounting Officer & Assistant Secretary | 0 | 1966 |
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.